Yağan Özgür, Taş Nilay, Mutlu Tuğçe, Hancı Volkan
Ordu University, School of Medicine, Department of Anesthesiology, Ordu, Turquia.
Ordu University, School of Medicine, Department of Anesthesiology, Ordu, Turquia.
Rev Bras Anestesiol. 2017 Mar-Apr;67(2):147-152. doi: 10.1016/j.bjan.2015.08.004. Epub 2016 Sep 28.
The aim of our study is to compare the effects of sugammadex and neostigmine, used for neuromuscular blockage antagonism, on postoperative nausea and vomiting (PONV).
Our study was completed with 98 ASA I-II risk patients undergoing endotracheal intubation under general anesthesia. At the end of the surgery patients were randomly allocated into two groups given 2mgkg sugammadex (Group S) or 50μgkg neostigmine plus 0.2mgkg atropine (Group N). Monitoring and recording times were set as 1 hour postoperative and from 1-6, 6-12, and 12-24hours. The anti-emetic amounts administered were recorded.
In the first postoperative hour 13 patients in Group N (27%) and 4 in Group S (8%) were observed to have nausea and/or vomiting and the difference was statistically significant (p=0.0016). During the 24hours of monitoring there was no significant difference in the incidence and severity of PONV (p>0.05), however the number of patients given ondansetron for PONV treatment in Group N was significantly higher than the number in Group S (16 in Group N, 6 in Group S, p<0.011).
At the end of our study comparing neostigmine with sugammadex for neuromuscular blockage antagonism, we found use of sugammadex had lower incidence of PONV in the postoperative 1st hour and less anti-emetic use in 24hours of monitoring.
本研究旨在比较用于拮抗神经肌肉阻滞的舒更葡糖钠和新斯的明对术后恶心呕吐(PONV)的影响。
本研究纳入了98例美国麻醉医师协会(ASA)分级为I-II级、在全身麻醉下行气管插管的患者。手术结束时,患者被随机分为两组,分别给予2mg/kg舒更葡糖钠(S组)或50μg/kg新斯的明加0.2mg/kg阿托品(N组)。监测和记录时间设定为术后1小时以及术后1-6小时、6-12小时和12-24小时。记录使用的止吐药物剂量。
术后第1小时,N组有13例患者(27%)出现恶心和/或呕吐,S组有4例患者(8%)出现,差异有统计学意义(p = 0.0016)。在24小时的监测期间,PONV的发生率和严重程度无显著差异(p>0.05),然而,N组因PONV接受昂丹司琼治疗的患者数量显著高于S组(N组16例,S组6例,p<0.011)。
在我们比较新斯的明和舒更葡糖钠用于拮抗神经肌肉阻滞的研究结束时,我们发现使用舒更葡糖钠在术后第1小时PONV的发生率较低,且在24小时监测期间使用的止吐药物较少。